Indications -- Psoriasis/Chronic Inflammation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- Psoriasis/Chronic Inflammation

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Mark Bong who wrote (174)	2/25/2002 2:52:50 PM
From: aknahow	of 631

Mark, this sounds good. "More than 30 percent of responders had 90 percent or greater PASI improvement from baseline." The release presents not a rehash but new information on 24 weeks of treatment and the early response rate. One of the reasons the p.r. may not seem good to you is there is n error in the release. Genetech made the error and has been informed by XOMA.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next